Stay updated with breaking news from Hal Barron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As the former boss of Glaxo's consumer healthcare division, Emma Walmsley (pictured) has never been in doubt that it is a crown jewel buried within the pharmaceuticals and vaccine champion.
As the former boss of Glaxo's consumer healthcare division, Emma Walmsley (pictured) has never been in doubt that it is a crown jewel buried within the pharmaceuticals and vaccine champion.
Nucala Approved for Chronic Rhinosinusitis With Nasal Polyps Credit: GlaxoSmithKline The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. The approval was based on data from the randomized, double-blind, parallel group phase 3 SYNAPSE study (ClinicalTrials.gov Identifier: NCT03085797), which evaluated the efficacy and safety of mepolizumab, an interleukin-5 antagonist monoclonal antibo...
A failure to create a Covid vaccine has now become a symbol of what are believed to be bigger issues with Dame Emma’s leadership
.jpg)
FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19 The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a treatment for coronavirus disease 2019 (COVID-19). The regulatory agency granted an Emergency Use Authorization (EUA) for sotrovimab, previously called VIR-7831, to treat mild to moderate COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The therapy, which was developed by GlaxoSmithKline (GSK) and Vir Biotechnology, is a single-dose monoclonal ...